Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...

Key abstracts on multiple myeloma from the 2025 American Society of Hematology Annual Meeting are reported by Dr Joseph Mikhael, chief medical officer of the International Myeloma Foundation. Dr ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition develops into multiple myeloma. The FDA has approved Johnson & Johnson’s ...

Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease from universally fatal to curable for a substantial proportion of patients.

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

Bristol Myers Squibb has ended its R&D losing streak with a hit on one of the dual primary endpoints in a phase 3 multiple myeloma trial. But with the study continuing to evaluate the other primary ...

Multiple myeloma is a form of blood cancer you may never have heard of–and that makes sense, because it’s, thankfully, pretty rare. That said, if you’re one of the unlucky few (your average lifetime ...